CDMO

← All Categories

• Korea's Biopharma Makes Its Case at BIO USA 2026 July 7, 2026

  Korean drugmakers from SK Biopharm to DXVX used BIO USA 2026 to court partners across CDMO, clinical analytics and licensing pipelines.

• Korean Biotech's Four-Day Push at BIO USA 2026 July 6, 2026

  Korean pharma and biotech firms used a packed four-day BIO USA 2026 schedule to court partners, from Kanaph Therapeutics to SK Biopharm and DXVX.